EP3666896A1 — Therapeutic inhibition of lactate dehydrogenase and agents therefor
Assigned to Novo Nordisk Health Care AG · Expires 2020-06-17 · 6y expired
What this patent protects
This invention relates to double-stranded nucleic acids that reduce expression of theLDHAgene by targeting lactate dehydrogenase mRNA for use in the treatment of PHI, PH2, PH3 (primary hyperoxaluria Type 1, Type 2 or Type 3) or idiopathic hyperoxaluria, e.g., Dicer substrate siRN…
USPTO Abstract
This invention relates to double-stranded nucleic acids that reduce expression of theLDHAgene by targeting lactate dehydrogenase mRNA for use in the treatment of PHI, PH2, PH3 (primary hyperoxaluria Type 1, Type 2 or Type 3) or idiopathic hyperoxaluria, e.g., Dicer substrate siRNA (DsiRNA) agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.